Literature DB >> 1606731

Low-affinity antibodies against collagen type II produced by lymph node cells are associated with pathology in collagen-induced arthritis in rats.

J Rahman1, J Loh, N A Staines.   

Abstract

The relationship between the affinity of antibodies against type II collagen (CII) and arthritis was studied in rats immunized intradermally with bovine CII. Disease was associated with a higher mean titre of serum antibody and a lower mean functional antibody affinity (determined in a chaotropic dissociation assay) against both the immunizing bovine CII and homologous autoantigenic rat CII in comparison with the response in immunized rats that did not develop disease. The functional affinity of the antibodies present in the serum was found to correlate with that of antibodies produced in culture by cells from the lymph nodes draining the site of immunization with collagen. The reduction in mean functional affinity in the anti-collagen response may be the result of the increased production of antibodies of the lowest affinity and a consequent broadening of the affinity heterogeneity. It is proposed that production of low-affinity antibodies in the lymph nodes draining the site of immunization with collagen is important in the pathogenesis of collagen-induced arthritis in rats.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606731      PMCID: PMC1554509          DOI: 10.1111/j.1365-2249.1992.tb06472.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Contribution of the spleen, lymph nodes and bone marrow to the antibody response in collagen-induced arthritis in the rat.

Authors:  J Rahman; N A Staines
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

2.  Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies.

Authors:  R Holmdahl; K Rubin; L Klareskog; E Larsson; H Wigzell
Journal:  Arthritis Rheum       Date:  1986-03

3.  Determination of the functional affinity of IgG1 and IgG4 antibodies to tetanus toxoid by isotype-specific solid-phase assays.

Authors:  M E Devey; K Bleasdale; S Lee; S Rath
Journal:  J Immunol Methods       Date:  1988-01-21       Impact factor: 2.303

4.  The use of ammonium sulphate globulin precipitation for determination of affinity of anti-protein antibodies in mouse serum.

Authors:  M W Steward; R E Petty
Journal:  Immunology       Date:  1972-05       Impact factor: 7.397

5.  Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats.

Authors:  H S Thompson; N A Staines
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

6.  Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis.

Authors:  M C Boissier; X Z Feng; A Carlioz; R Roudier; C Fournier
Journal:  Ann Rheum Dis       Date:  1987-09       Impact factor: 19.103

7.  Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen.

Authors:  C Nagler-Anderson; L A Bober; M E Robinson; G W Siskind; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

8.  Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity.

Authors:  N Seki; Y Sudo; T Yoshioka; S Sugihara; T Fujitsu; S Sakuma; T Ogawa; T Hamaoka; H Senoh; H Fujiwara
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

9.  Tolerogenic activity of polymerized type II collagen in preventing collagen-induced arthritis in rats.

Authors:  H S Thompson; B Henderson; J M Spencer; S M Hobbs; J V Peppard; N A Staines
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

10.  Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci.

Authors:  W C Watson; A S Townes
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.